Globe Pulsed Field System; Globe Catheter
Kardium, Inc. · Decision date Oct 23, 2026
What did the FDA decide?
The FDA record for P240044/S008 describes a 30-Day Notice submitted by Kardium, Inc. for the Globe Pulsed Field System and Globe Catheter, a percutaneous cardiac ablation catheter for atrial fibrillation using irreversible electroporation. The stated change is a modification to the sterilization cycle parameters and the use of a larger maximum sterilization load.
The listed reason is a process change involving the manufacturer, sterilizer, packager or supplier. This supplement sits under the original PMA identifier P240044; the record does not establish the original approval date, prior sterilization settings, or the specific parameter values changed. The statement reports the applicant's stated purpose, not independent evidence of safety or clinical effectiveness, and the decision date in the record is 2026-10-23.
FDA approval order statement
modification to the sterilization cycle parameters and use of a larger maximum sterilization load
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 23, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240044/S008
- Regulatory pathway
- PMA supplement
- Applicant
- Kardium, Inc.
- Product code
- QZI
- Decision code
- OK30
- Decision date
- Oct 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Kardium, Inc.
- Product code
- QZI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240044. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240044 · Original PMA
Globe Pulsed Field System
P240044/S008 received
Application receipt date recorded by FDA.
P240044/S008 · FDA decision
30-Day Notice
P240044/S007 · Related supplement
Globe Catheter and Globe Pulsed Field System
Timeline entries are records held by MedtechLedger for P240044. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240044
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Globe Pulsed Field SystemP240044 | Kardium, Inc. | PMA approval | Aug 27, 2025 | FDA |
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
Volt PFA Catheter, Sensor EnabledP250022/S009 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
VOLT PFA CATHETER, SENSOR ENABLEDP250022/S012 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Kardium, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 8518 Glenlyon Pkwy., Unit 155, Burnaby, V5J OB6
Sources and methodology
- Original FDA record: P240044/S008
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

